PIK3CA and non-small cell lung carcinoma: In the phase I trial of PX‐866 in combination with docetaxel, there was one NSCLC patient with a PIK3CA mutation who had a prolonged response to continuation PX‐866 after cessation of docetaxel.86 Buparlisib has also been investigated as monotherapy in the BASALT‐1 phase II trial of previously treated patients with NSCLC.63 Patients were selected based on identification of PI3K pathway activation.